This marks Jacobio's successful transformation from the early R&D stage to an innovation-driven value realization stage," said Dr.Yinxiang Wang, the Chairman and CEO of Jacobio Pharma. "Looking ahead ...

This month's cover highlights the article Nup358 restricts ER-mitochondria connectivity by modulating mTORC2/Akt/GSK3β signalling by Joseph, Misha Kalarikkal and colleagues. The image shows a human ...

The paper titled,“Discovery of Rezatapopt (PC14586), a First-in-Class, Small-Molecule Reactivator of p53 Y220C Mutant in Development” can be accessed here . Announced a partnership with ...

Enrollment on track in Phase 2 pivotal portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS ... therapies targeting p53, today reported ...

Enrollment on track in Phase 2 pivotal portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced ... tumor-agnostic therapies ...

Researchers from PMV Pharmaceuticals Inc. and collaborators described the effect of rezatapopt (PC-14586), a first-in-class selective p53 reactivator designed to reinstate p53 Y220C mutant function.

It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. Receive News & Ratings for PMV ...

PC14586, a novel small-molecule p53 reactivator, selectively binds to a specific pocket in the TP53 Y220C mutant protein, aiming to restore the conformation and transcriptional activity of wild-type ...

MANILA – The Philippine Economic Zone Authority (Peza) has approved P52.93 billion worth of investment pledges in the first two months of the year. PEZA reported Tuesday that its investment ...

Figure 8: Regulation of ALDH3A1 and NECTIN4 by p53. Researchers Jessica J. Miciak, Lucy Petrova, Rhythm Sajwan, Aditya Pandya, Mikayla Deckard, Andrew J. Munoz, and Fred Bunz from the Sidney ...

A new research paper was published in Oncotarget, Volume 16, on February 18, 2025, titled "Robust p53 phenotypes and prospective downstream targets in telomerase-immortalized human cells.